利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.027 秒)

    Brain targeted low molecular weight hydrophobic antioxidant compounds
    1.
    发明授权
    Brain targeted low molecular weight hydrophobic antioxidant compounds 失效
    脑靶向低分子量疏水性抗氧化剂

    公开(公告)号：US06420429B1

    公开(公告)日：2002-07-16

    申请号：US09322980

    申请日：1999-06-01

    申请人： Daphne Atlas ,  Eldad Melamed ,  Daniel Offen

    发明人： Daphne Atlas ,  Eldad Melamed ,  Daniel Offen

    IPC分类号： A61K31165

    CPC分类号： A61K31/16

    摘要： Novel brain targeted low molecular weight, hydrophobic antioxidants and use of antioxidants in treatment of central nervous system neurodegenerative disorders such as Parkinson's, Alzheimer's and Creutzfeldt-Jakob's diseases and in treatment of conditions of peripheral tissues, such as acute respiratory distress syndrome, amyotrophic lateral sclerosis, atheroscierotic cardiovascular disease and multiple organ dysfunction, in which oxidants are overproduced.

    摘要翻译： 靶向低分子量，疏水性抗氧化剂和抗氧化剂用于治疗中枢神经系统神经退行性疾病如帕金森病，阿尔茨海默病和克雅氏病以及治疗周围组织病症如急性呼吸窘迫综合征，肌萎缩性侧索硬化症 ，动脉粥样硬化心血管疾病和多器官功能障碍，其中氧化剂过量产生。

    Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
    2.
    发明授权
    Treatment of ischemic brain injuries with brain targeted anti oxidant compounds 失效
    用脑靶向抗氧化剂治疗缺血性脑损伤

    公开(公告)号：US06369106B1

    公开(公告)日：2002-04-09

    申请号：US09472033

    申请日：1999-12-27

    申请人： Daphne Atlas ,  Eldad Melamed ,  Daniel Offen

    发明人： Daphne Atlas ,  Eldad Melamed ,  Daniel Offen

    IPC分类号： A61K31225

    CPC分类号： A61K38/063 ,  A61K31/00 ,  A61K31/16 ,  A61K31/198 ,  A61K31/216 ,  A61K31/223 ,  A61K38/05 ,  C07C323/59 ,  C07K5/0215

    摘要： A method of reducing oxidative stress in the brain of an organism having a blood brain barrier and suffering an ischemic brain injury, the method comprising the step of administering a compound to the organism, the compound having (a) a combination of molecular weight and membrane miscibility properties for permitting the compound to cross the blood brain barrier of the organism; (b) a readily oxidizable chemical group for exerting antioxidation properties; and (c) a chemical make-up for permitting the compound or its intracellular derivative to accumulate within the cytoplasm of cells.

    摘要翻译： 一种降低具有血脑屏障并发生缺血性脑损伤的生物体的脑中的氧化应激的方法，所述方法包括向所述生物体施用化合物的步骤，所述化合物具有（a）分子量和膜的组合 允许化合物穿过生物体的血脑屏障的混溶性; （b）易氧化的化学基团，用于发挥抗氧化性能; 和（c）使化合物或其细胞内衍生物在细胞的细胞质内积累的化学成分。

    Process for preparing ethyl ester of L-DOPA
    4.
    发明授权
    Process for preparing ethyl ester of L-DOPA 失效
    制备L-DOPA乙酯的方法

    公开(公告)号：US5354885A

    公开(公告)日：1994-10-11

    申请号：US995847

    申请日：1992-12-24

    申请人： Isaac Milman ,  Alexander Veinberg ,  Daphne Atlas ,  Eldad Melamed

    发明人： Isaac Milman ,  Alexander Veinberg ,  Daphne Atlas ,  Eldad Melamed

    IPC分类号： A61K9/08 ,  A61K31/195 ,  A61K31/215 ,  A61K31/216 ,  A61K47/02 ,  A61K47/12 ,  A61P25/00 ,  A61P25/16 ,  C07C229/36 ,  C07C229/00 ,  A61K31/135

    CPC分类号： A61K31/216 ,  A61K31/195 ,  A61K31/215

    摘要： A composition which comprises a pharmaceutically acceptable carrier and an active ingredient, such active ingredient comprising L-DOPA ethyl ester in an amount which is at least 97%, by weight, of the active ingredient, and L-DOPA in an amount which is less than 1% by weight of such active ingredient is provided by this invention. This invention also provides a process for preparing such a composition. Further, this invention provides a method of treating a patient suffering from Parkinson's disease which comprises administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of L-DOPA ethyl ester and a pharmaceutically acceptable carrier.

    摘要翻译： 一种组合物，其包含药学上可接受的载体和活性成分，所述活性成分包含至少97重量％的活性成分的L-DOPA乙酯，L-DOPA的量少 超过1重量％的这种活性成分由本发明提供。 本发明还提供了制备这种组合物的方法。 此外，本发明提供了治疗患有帕金森病的患者的方法，其包括向患者施用包含治疗有效量的L-DOPA乙酯和药学上可接受的载体的药物组合物。

    Compositions of the ethyl ester of L-DOPA
    6.
    发明授权
    Compositions of the ethyl ester of L-DOPA 失效
    L-DOPA乙酯的组成

    公开(公告)号：US5525631A

    公开(公告)日：1996-06-11

    申请号：US276196

    申请日：1994-07-18

    申请人： Isaac Milman ,  Alexander Veinberg ,  Daphne Atlas ,  Eldad Melamed

    发明人： Isaac Milman ,  Alexander Veinberg ,  Daphne Atlas ,  Eldad Melamed

    IPC分类号： A61K9/08 ,  A61K31/195 ,  A61K31/215 ,  A61K31/216 ,  A61K47/02 ,  A61K47/12 ,  A61P25/00 ,  A61P25/16 ,  C07C229/36 ,  A61K31/135 ,  C07C229/00

    CPC分类号： A61K31/216 ,  A61K31/195 ,  A61K31/215

    摘要： A composition which comprises a pharmaceutically acceptable carrier and an active ingredient, such active ingredient comprising L-DOPA ethyl ester derived from its crystaline form in an amount which is at least 97%, by weight, of the active ingredient, and L-DOPA in an amount which is less than 1% by weight of such active ingredient is provided by this invention. This invention also provides a process for preparing such a composition. Further, this invention provides a method of treating a patient suffering from Parkinson's disease which comprises administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of L-DOPA ethyl ester derived from its crystaline form and a pharmaceutically acceptable carrier.

    摘要翻译： 一种组合物，其包含药学上可接受的载体和活性成分，所述活性成分包含衍生自其结晶形式的L-DOPA乙酯，其量为活性成分的至少97重量％，L-DOPA为 这种活性成分的量小于1重量％是由本发明提供的。 本发明还提供了制备这种组合物的方法。 此外，本发明提供了治疗患有帕金森病的患者的方法，其包括向患者施用包含治疗有效量的衍生自其结晶形式的L-DOPA乙酯和药学上可接受的载体的药物组合物。

    GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS
    9.
    发明申请
    GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS 有权
    表达神经营养因子的遗传性改良的肌肉细胞

    公开(公告)号：US20130344041A1

    公开(公告)日：2013-12-26

    申请号：US14002782

    申请日：2012-03-01

    申请人： Daniel Offen ,  Michal Dadon-Nachum ,  Tali Ben-Zur ,  Eldad Melamed ,  David Yaffe

    发明人： Daniel Offen ,  Michal Dadon-Nachum ,  Tali Ben-Zur ,  Eldad Melamed ,  David Yaffe

    IPC分类号： C12N5/077

    CPC分类号： A61K35/34 ,  A61K35/12 ,  A61K38/00 ,  A61K38/185 ,  A61K38/1866 ,  A61K38/30 ,  C12N5/0658 ,  C12N5/0659 ,  C12N2501/105 ,  C12N2501/13 ,  C12N2501/165 ,  C12N2510/00

    摘要： An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.

    摘要翻译： 公开了分离的肌肉祖细胞是MyoD阳性，CD34阴性和CD45阴性。 肌肉祖细胞被遗传修饰以表达至少一种神经营养因子。 此外，公开了包含至少四个肌细胞亚群的细胞群，每个亚群被遗传修饰以表达不同的神经营养因子，其中所述神经营养因子选自神经胶质细胞衍生的神经营养因子（GDNF），胰岛素生长因子 IGF-1），血管内皮生长因子（VEGF）和脑源性神经营养因子（BDNF）。 还公开了细胞群体的用途。